Sustainability Commitment
Our commitment reflects our focus on improving health and safety through a people-centric culture, ethical leadership, and climate stewardship.
Purpose-Driven and Future-Focused
Our mission to improve patient health and safety guides everything we do—and shapes our commitment to sustainability. This deep sense of responsibility is reflected in how we operate as a business, with a focus on People-Centric Culture, Ethical Leadership, and Climate Stewardship.
Our SBTi-validated emissions reduction targets and EcoVadis Commitment badge reflect continued progress, and as part of our journey, have detailed action plans to continuously improve our rating.
Sustainability Starts with Our Core Principles
People-Centric Culture
We foster a culture of respect, inclusion, and opportunity to enable employee well-being, professional growth, and a culture of belonging.
- Dedicated DEI program and leadership
- Risk inventory assessments
- Volunteer and flexible time off
- Wellness benefits, annual programming, and challenges
- Employee Resource Groups and clubs
- Feedback and upward mobility
- Charity match programs
- Talent acquisition and retention
- Mentorship programs
- Training and continuous education opportunities
- And more!
Ethical Leadership
We uphold integrity, transparency, and accountability in all aspects of our business, ensuring responsible decision-making, data privacy, and compliance with global standards.
- Advanced Data Security and Privacy Programs
- Compliance with labor laws within each operating region
- Quarterly Board Reporting on Sustainability Program
- Transparent and accessible leadership through Town Halls
Climate Stewardship
We are focused on minimizing our environmental footprint through science-based climate action, responsible resource management, and continuous improvement in sustainability practices.
- Remote workforce commitment
- Employee Education & Green Team
- EcoVadis Commitment Badge
- Approved near- and long-term science-based emissions reduction targets with the Science Based Targets initiative (SBTi)
- Annual energy and carbon reporting
Our near-term and long-term emissions reduction targets have been independently validated by SBTi Services in accordance with the SBTi Near-Term and Net-Zero Criteria.
Driving Progress Through Collaboration
Our Sustainability Program is guided by a dedicated Steering Committee made up of executive and senior leaders from across our global operations. This cross-functional group is responsible for driving progress across all pillars of our sustainability strategy. The committee ensures accountability, approves new initiatives, and proactively plans for evolving regional requirements and standards to maintain meaningful, forward-looking impact.
News & Insights
May 5, 2026
IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strat...
Preparing for an IND submission? Discover 12 critical questions sponsors should answer to reduce FDA risk, avoid delays, and strengthen submission readiness.
April 30, 2026
Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity ...
Recent cyberattacks on MedTech leaders highlight growing regulatory and patient safety risks. Explore key lessons and how FDA cybersecurity guidance is shaping compliance and resilience.
January 27, 2026
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...
ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.
December 11, 2025
ProPharma Expands Operations with New Office in Hyderabad
ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
May 4, 2026
IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting
A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...
April 20, 2026
Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...
Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...
June 2, 2026
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution
A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...
April 23, 2026
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market
As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...
News & Insights
May 4, 2026
IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting
A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...
April 20, 2026
Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...
Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...